COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Neoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast Cancer (APTneo)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03595592
Recruitment Status : Recruiting
First Posted : July 23, 2018
Last Update Posted : August 9, 2019
Hoffmann-La Roche
Information provided by (Responsible Party):
Fondazione Michelangelo

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : December 15, 2026
Estimated Study Completion Date : June 15, 2027